

**UNITED STATES INTERNATIONAL TRADE COMMISSION**  
**Washington, D.C.**

**In the Matter of**

**CERTAIN BLOOD CHOLESTEROL  
TESTING STRIPS AND ASSOCIATED  
SYSTEMS CONTAINING THE SAME**

**Investigation No. 337-TA-1116**

**NOTICE OF COMMISSION DETERMINATION NOT TO REVIEW AN INITIAL  
DETERMINATION TERMINATING THE INVESTIGATION AS TO CERTAIN  
CLAIMS OF U.S. PATENT NO. 7,087,397**

**AGENCY:** U.S. International Trade Commission.

**ACTION:** Notice.

**SUMMARY:** Notice is hereby given that the U.S. International Trade Commission (“Commission”) has determined not to review a January 30, 2019 initial determination (“ID”) (Order No. 10) terminating the investigation as to claims 13, 14, and 20 of U.S. Patent No. 7,087,397.

**FOR FURTHER INFORMATION CONTACT:** Ron Traud, Office of the General Counsel, U.S. International Trade Commission, 500 E Street SW., Washington, DC 20436, telephone (202) 205-3427. Copies of non-confidential documents filed in connection with this investigation are or will be available for inspection during official business hours (8:45 a.m. to 5:15 p.m.) in the Office of the Secretary, U.S. International Trade Commission, 500 E Street SW., Washington, DC 20436, telephone (202) 205-2000. General information concerning the Commission may also be obtained by accessing its Internet server (<https://www.usitc.gov>). The public record for this investigation may be viewed on the Commission’s Electronic Docket Information System (“EDIS”) (<https://edis.usitc.gov>). Hearing-impaired persons are advised that information on this matter can be obtained by contacting the Commission’s TDD terminal, telephone (202) 205-1810.

**SUPPLEMENTARY INFORMATION:** On June 5, 2018, the Commission instituted this investigation based on an amended complaint filed on behalf of Polymer Technology Systems, Inc. of Indianapolis, Indiana (“PTS”). 83 FR 26087 (June 5, 2018). The complaint alleges violations of section 337 of the Tariff Act of 1930, as amended, 19 U.S.C. 1337, based upon the importation into the United States, the sale for importation, and the sale within the United States after importation of certain blood cholesterol testing strips and associated systems containing the same by reason of infringement of one or more of claims 1–3, 5, 10, 13–14, and 17–20 of U.S. Patent No. 7,087,397 (“the ’397 patent”); claims 1–9 and 13–15 of U.S. Patent No. 7,625,721; and claims 8–11 of U.S. Patent No. 7,494,818. *Id.* The Commission’s notice of investigation

named as respondents ACON Laboratories, Inc. of San Diego, California; and ACON Biotech (Hangzhou) Co., Ltd., of Hangzhou Zhejiang, China. *Id.* The Office of Unfair Import Investigations was not named as a party in this investigation. *Id.*

On December 12, 2018, PTS filed an unopposed motion pursuant to Commission Rule 210.21(a) (19 CFR 210.21(a)) requesting termination of this investigation as to claims 13, 14, and 20 of the '397 patent.

On January 30, 2019, the presiding administrative law judge issued Order No. 10, the subject ID, granting the motion. The ID finds that the motion complied with the Commission's rules and that no extraordinary circumstances warrant denying the motion. No party filed a petition seeking review of the subject ID. The Commission has determined not to review the ID.

The authority for the Commission's determination is contained in section 337 of the Tariff Act of 1930, as amended (19 U.S.C. 1337), and in part 210 of the Commission's Rules of Practice and Procedure (19 CFR part 210).

By order of the Commission.

A handwritten signature in black ink, appearing to read 'Lisa R. Barton', is positioned above the typed name.

Lisa R. Barton  
Secretary to the Commission

Issued: February 21, 2019